Gene-Guided cancer drug dosing: a smarter way to treat neuroendocrine tumors?
NCT ID NCT06406465
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 39 times
Summary
This phase 2 trial tests whether adjusting the dose of the cancer drug belinostat based on a person's genetic makeup can improve treatment for high-grade neuroendocrine carcinomas. Researchers will give 60 participants different doses of belinostat along with standard chemotherapy (cisplatin and etoposide) based on their UGT1A1 gene variant. The goal is to see if this personalized approach leads to more consistent drug levels in the body and better tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belinostat (a cancer drug) combined with cisplatin and etoposide
What this could lead to
If successful, this could show that adjusting belinostat doses based on a person's genes makes the treatment safer and more effective for neuroendocrine cancer.
What could go wrong
This is a small, early-phase trial (60 people) focused on drug levels, not a proven cure. The genetic approach may not improve outcomes, and side effects from the chemotherapy combination are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.